← FDA ENFORCEMENT
D-0230-2026Class II

Novocol Pharmaceutical of Canada, Inc.

Recalling firm
Novocol Pharmaceutical of Canada, Inc.
Product type
Drug
Status
Ongoing
Report date
2025-12-24
Distribution
U.S.A. Nationwide
Product quantity
5,825
Initiated by
Voluntary: Firm initiated
Reason for recall

Defective container: cracked/broken cartridges

Product description

3% Polocaine DENTAL, Mepivacaine Hydrochloride 3% (30mg/mL) (Mepivacaine HCI Injection, USP), packaged in a carton containing 50 single-dose Cartridges, 1.7 ml each, Rx only, Manufactured for Dentsply Pharmaceutical, York, PA 17404, by Novocol Pharmaceutical of Canada, Inc., NDC 66312-441-16.

Code / lot info

Lot: D05159C, expires: 07-31-2027

Data: U.S. FDA openFDA enforcement API. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification.